CAPTRUST Financial Advisors
CORT icon

CAPTRUST Financial Advisors’s Corcept Therapeutics CORT Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.26M Buy
37,447
+13,652
+57% +$824K 0.01% 1030
2026
Q1 		$959K Buy
23,795
+14,373
+153% +$537K ﹤0.01% 1640
2025
Q4 		$328K Sell
9,422
-1,426
-13% -$112K ﹤0.01% 2180
2025
Q3 		$902K Buy
10,848
+2,717
+33% +$197K ﹤0.01% 1485
2025
Q2 		$597K Sell
8,131
-1,001
-11% -$72.6K ﹤0.01% 1624
2025
Q1 		$1.04M Sell
9,132
-104,856
-92% -$6.38M ﹤0.01% 1246
2024
Q4 		$5.74M Buy
113,988
+10,248
+10% +$537K 0.02% 501
2024
Q3 		$4.8M Sell
103,740
-19,255
-16% -$684K 0.01% 542
2024
Q2 		$4M Sell
122,995
-6,676
-5% -$183K 0.01% 562
2024
Q1 		$3.27M Sell
129,671
-12,401
-9% -$293K 0.01% 624
2023
Q4 		$4.61M Sell
142,072
-908
-0.6% -$24.9K 0.02% 585
2023
Q3 		$3.9M Sell
142,980
-85,187
-37% -$2.47M 0.01% 606
2023
Q2 		$5.08M Buy
228,167
+621
+0.3% +$14.3K 0.02% 502
2023
Q1 		$4.93M Buy
227,546
+208,844
+1,117% +$4.58M 0.02% 464
2022
Q4 		$380K Buy
18,702
+147
+0.8% +$3.69K ﹤0.01% 1488
2022
Q3 		$476K Buy
18,555
+10,923
+143% +$292K ﹤0.01% 1275
2022
Q2 		$181K Buy
7,632
+827
+12% +$18K ﹤0.01% 1758
2022
Q1 		$153K Buy
6,805
+3,181
+88% +$67.7K ﹤0.01% 1924
2021
Q4 		$72K Buy
3,624
+256
+8% +$5.19K ﹤0.01% 2389
2021
Q3 		$66K Buy
3,368
+37
+1% +$774 ﹤0.01% 2390
2021
Q2 		$73K Sell
3,331
-644
-16% -$14.3K ﹤0.01% 2249
2021
Q1 		$95K Buy
3,975
+3,755
+1,707% +$100K ﹤0.01% 1995
2020
Q4 		$6K Buy
220
+100
+83% +$2.11K ﹤0.01% 2762
2020
Q3 		$2K Buy
+120
New +$1.91K ﹤0.01% 2745

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CAPTRUST Financial Advisors's CORT Position: Q2 2026 in Review

CAPTRUST Financial Advisors increased its Corcept Therapeutics (CORT) stake by 57% in Q2 2026, buying an estimated $824K and bringing the position to 37,447 shares worth $3.26M. The position accounts for 0.01% of the portfolio, ranked #1030.

CAPTRUST Financial Advisors first reported a position in CORT in Q3 2020 and has held it in 24 quarters since. The position peaked at $5.74M in Q4 2024. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • CAPTRUST Financial Advisors held 37,447 shares of Corcept Therapeutics worth $3.26M as of Q2 2026.
  • CAPTRUST Financial Advisors bought 13,652 Corcept Therapeutics shares in Q2 2026, an estimated $824K.
  • Corcept Therapeutics made up 0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #1030 holding.
  • CAPTRUST Financial Advisors first reported a position in Corcept Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • CAPTRUST Financial Advisors's Corcept Therapeutics position peaked at $5.74M in Q4 2024.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.